Vanguard Group
RCEL icon

Vanguard Group’s Avita Medical RCEL Stock Holding History

Vanguard Group’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.98M Buy
1,444,579
+79,102
+6% +$316K ﹤0.01% 3255
2025
Q3 		$6.98M Sell
1,365,477
-84,890
-6% -$443K ﹤0.01% 3162
2025
Q2 		$7.67M Buy
1,450,367
+16,536
+1% +$120K ﹤0.01% 3042
2025
Q1 		$11.7M Buy
1,433,831
+10,392
+0.7% +$97.1K ﹤0.01% 2763
2024
Q4 		$18.2M Buy
1,423,439
+5,767
+0.4% +$68K ﹤0.01% 2628
2024
Q3 		$15.2M Buy
1,417,672
+21,971
+2% +$206K ﹤0.01% 2739
2024
Q2 		$11.1M Sell
1,395,701
-12,435
-0.9% -$118K ﹤0.01% 2857
2024
Q1 		$22.6M Buy
1,408,136
+15,356
+1% +$249K ﹤0.01% 2541
2023
Q4 		$19.1M Buy
1,392,780
+32,084
+2% +$368K ﹤0.01% 2615
2023
Q3 		$19.9M Buy
1,360,696
+11,062
+0.8% +$187K ﹤0.01% 2556
2023
Q2 		$23M Buy
1,349,634
+143,802
+12% +$2.11M ﹤0.01% 2535
2023
Q1 		$16.8M Buy
1,205,832
+57,506
+5% +$612K ﹤0.01% 2666
2022
Q4 		$7.58M Buy
1,148,326
+571
+0% +$3.42K ﹤0.01% 3085
2022
Q3 		$6.05M Hold
1,147,755
– – ﹤0.01% 3220
2022
Q2 		$5.45M Sell
1,147,755
-129,222
-10% -$798K ﹤0.01% 3337
2022
Q1 		$10.8M Buy
1,276,977
+6,467
+0.5% +$59.6K ﹤0.01% 3108
2021
Q4 		$15.2M Buy
1,270,510
+8,562
+0.7% +$131K ﹤0.01% 2977
2021
Q3 		$22.4M Sell
1,261,948
-33,543
-3% -$633K ﹤0.01% 2807
2021
Q2 		$26.6M Buy
1,295,491
+231,520
+22% +$4.56M ﹤0.01% 2695
2021
Q1 		$21.1M Buy
1,063,971
+721,346
+211% +$16.8M ﹤0.01% 2760
2020
Q4 		$6.37M Buy
342,625
+57,714
+20% +$1.27M ﹤0.01% 3240
2020
Q3 		$7.17M Buy
+284,911
New +$7.1M ﹤0.01% 2968

Other funds holding RCEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group's RCEL Position: Q4 2025 in Review

Vanguard Group increased its Avita Medical (RCEL) stake by 5.8% in Q4 2025, buying an estimated $316K and bringing the position to 1,444,579 shares worth $4.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3255.

Vanguard Group first reported a position in RCEL in Q3 2020 and has held it in 22 quarters since. The position peaked at $26.6M in Q2 2021. 67 funds tracked by Wall St. Rank hold RCEL as of Q4 2025.

  • Vanguard Group held 1,444,579 shares of Avita Medical worth $4.98M as of Q4 2025.
  • Vanguard Group bought 79,102 Avita Medical shares in Q4 2025, an estimated $316K.
  • Avita Medical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3255 holding.
  • Vanguard Group first reported a position in Avita Medical in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's Avita Medical position peaked at $26.6M in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Avita Medical as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.